258 related articles for article (PubMed ID: 29978156)
1. Canagliflozin-associated diabetic ketoacidosis: a case report.
Chai PR; Bonney C; Blohm E; Boyer EW; Babu KM
Toxicol Commun; 2017; 1(1):2-5. PubMed ID: 29978156
[TBL] [Abstract][Full Text] [Related]
2. Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report.
Fukuda M; Nabeta M; Muta T; Fukami K; Takasu O
Int J Emerg Med; 2020 Jan; 13(1):2. PubMed ID: 31969112
[TBL] [Abstract][Full Text] [Related]
3. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
Peters AL; Henry RR; Thakkar P; Tong C; Alba M
Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
[TBL] [Abstract][Full Text] [Related]
4. Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature.
Turner J; Begum T; Smalligan RD
J Investig Med High Impact Case Rep; 2016; 4(3):2324709616663231. PubMed ID: 27635409
[TBL] [Abstract][Full Text] [Related]
5. Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.
Kelmenson DA; Burr K; Azhar Y; Reynolds P; Baker CA; Rasouli N
J Investig Med High Impact Case Rep; 2017; 5(2):2324709617712736. PubMed ID: 28634592
[TBL] [Abstract][Full Text] [Related]
6. Prolonged diabetic ketoacidosis associated with canagliflozin.
Sloan G; Kakoudaki T; Ranjan N
Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 29899991
[TBL] [Abstract][Full Text] [Related]
7. SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review.
Mahfooz RS; Khan MK; Al Hennawi H; Khedr A
Cureus; 2022 Jun; 14(6):e26267. PubMed ID: 35911365
[TBL] [Abstract][Full Text] [Related]
8. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
Diaz-Ramos A; Eilbert W; Marquez D
Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
[TBL] [Abstract][Full Text] [Related]
9. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
[TBL] [Abstract][Full Text] [Related]
10. Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.
Bader N; Mirza L
Pak J Med Sci; 2016; 32(3):786-8. PubMed ID: 27375734
[TBL] [Abstract][Full Text] [Related]
11. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.
Ahmed M; McKenna MJ; Crowley RK
Endocr Pract; 2017 Apr; 23(4):506-508. PubMed ID: 28437153
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
13. Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
Andrews TJ; Cox RD; Parker C; Kolb J
J Emerg Med; 2017 Feb; 52(2):223-226. PubMed ID: 27717592
[TBL] [Abstract][Full Text] [Related]
14. ‘Euglycemic’ Ketoacidosis in a Patient With Type 2 Diabetes Being Treated With Canagliflozin.
Danford C; Chan P; Magill SB
WMJ; 2016 Aug; 115(4):206-9. PubMed ID: 29099159
[TBL] [Abstract][Full Text] [Related]
15. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
Erondu N; Desai M; Ways K; Meininger G
Diabetes Care; 2015 Sep; 38(9):1680-6. PubMed ID: 26203064
[TBL] [Abstract][Full Text] [Related]
16. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management.
Kum-Nji JS; Gosmanov AR; Steinberg H; Dagogo-Jack S
J Diabetes Complications; 2017 Mar; 31(3):611-614. PubMed ID: 27913012
[TBL] [Abstract][Full Text] [Related]
17. Acute pancreatitis in the use of canagliflozin: A rare side-effect of the novel therapy for type 2 diabetes mellitus.
Srivali N; Thongprayoon C; Cheungpasitporn W; Ungprasert P
J Basic Clin Pharm; 2015 Jun; 6(3):101-2. PubMed ID: 26229348
[TBL] [Abstract][Full Text] [Related]
18. Canagliflozin-associated Diabetic Ketoacidosis with Lower-than-anticipated Glucose Levels.
Vadi S; Agarwal M
Indian J Crit Care Med; 2017 Nov; 21(11):793-795. PubMed ID: 29279644
[TBL] [Abstract][Full Text] [Related]
19. Euglycemic diabetic ketoacidosis: A missed diagnosis.
Nasa P; Chaudhary S; Shrivastava PK; Singh A
World J Diabetes; 2021 May; 12(5):514-523. PubMed ID: 33995841
[TBL] [Abstract][Full Text] [Related]
20. Euglycemic Diabetic Ketoacidosis Caused by Alcoholic Pancreatitis and Starvation Ketosis.
Han HJ; Cole AE; Verma A
J Gen Intern Med; 2023 Apr; 38(5):1299-1301. PubMed ID: 36689144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
